NEW YORK, September 10, 2014 /PRNewswire/ --
Today, Analysts Review released its research reports regarding Jazz Pharmaceuticals plc (NASDAQ: JAZZ), Keryx Biopharmaceuticals (NASDAQ: KERX), Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX), WellPoint Inc. (NYSE: WLP) and GlaxoSmithKline plc (NYSE: GSK). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/6356-100free.
--
Jazz Pharmaceuticals plc Research Reports
On September 5, 2014, shares in Jazz Pharmaceuticals plc (Jazz) surged high by 7.11% to close the trading session at $168.02, after declining 4.17% in the previous trading session. Shares in Jazz opened the session at $156.62 and fluctuated between intra-day low of $153.92 and intra-day high of $168.88. A total of 3.29 million shares changed hands, which is significantly above its 30-day average volume of 1.02 million shares. The stock has a 52-week high of $176.60 and a 52-week low of $80.40. On August 5, 2014, Jazz had reported its Q2 2014 financial results with total revenues of $291.2 million, up 39.8% YoY, and net income attributable to Jazz of $43.7 million, up 3.5% YoY. Since the release of Q2 2014 earnings, the Company's stock has surged 23.73%. The full research reports on Jazz are available to download free of charge at:
http://www.analystsreview.com/Sep-10-2014/JAZZ/report.pdf
--
Keryx Biopharmaceuticals Research Reports
On September 5, 2014, Keryx Biopharmaceuticals (Keryx) announced that the U.S. Food and Drug Administration (FDA) approved Ferric Citrate (formerly known as Zerenex) for the control of serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis. The Company informed that Ferric Citrate's approval was based on data from its Phase 3 registration program. In the Phase 3 clinical trials, Ferric Citrate effectively reduced serum phosphorus levels to well within the KDOQI guidelines range of 3.5 mg/dL to 5.5 mg/dL. Ron Bentsur, CEO, Keryx, said, "We are thrilled with the FDA's decision to approve Ferric Citrate, and look forward to bringing it to market in the U.S. within the next 12 weeks. We are committed to bringing innovative therapies to the market for patients with kidney disease and are excited to be offering this important treatment option to dialysis patients." The full research reports on Keryx are available to download free of charge at:
http://www.analystsreview.com/Sep-10-2014/KERX/report.pdf
--
Vertex Pharmaceuticals Incorporated Research Reports
On September 5, 2014, shares in Vertex Pharmaceuticals Incorporated (Vertex) moved up 3.81% to close the trading session at $95.04, outperforming the Nasdaq Composite that gained 0.45% over the same trading session. Shares in Vertex opened the session at $94.68 and fluctuated between $93.55 and $96.31, with 2.07 million shares changing hands. Vertex stock has surged 27.91% on YTD basis, compared to Nasdaq Composite that gained 9.73% on YTD basis. Moreover, the stock is trading above its 50-day and 200-day moving average of $93.04 and $78.01, respectively. The full research reports on Vertex are available to download free of charge at:
http://www.analystsreview.com/Sep-10-2014/VRTX/report.pdf
--
WellPoint Inc. Research Reports
On September 3, 2014, WellPoint Inc. (WellPoint) announced that the Company's senior management will present at the upcoming Leerink Partners Services Roundtable on September 30, 2014 at 9:45 a.m. EDT. The Company informed that the webcast and replays of the presentation will be available on the Company official website under Investors link. The full research reports on WellPoint are available to download free of charge at:
http://www.analystsreview.com/Sep-10-2014/WLP/report.pdf
--
GlaxoSmithKline plc Research Reports
On September 8, 2014, GlaxoSmithKline plc (GSK) announced that the Company presented its data at the European Respiratory Society (ERS) Congress that show blood eosinophil (a type of white blood cell) levels may help predict those patients with COPD who will have a greater reduction in exacerbation rates when receiving an inhaled corticosteroid (ICS) containing regimen, and could potentially be used in the future, if supported by further studies, to help physicians tailor their treatment decisions. The Company stated that a number of scientific studies have suggested that eosinophils, although primarily associated with asthma, may also influence and be associated with an increased risk of exacerbations among patients with COPD. Neil Barnes, Global Franchise Medical Head, Respiratory, GSK said, "COPD is a heterogeneous disease and enhancing our understanding of how individual patients respond to different treatments is critical to allow treatment to be tailored to their specific needs, with the ultimate aim of improving outcomes." The full research reports on GSK are available to download free of charge at:
http://www.analystsreview.com/Sep-10-2014/GSK/report.pdf
--
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.
===============
EDITOR'S NOTES:
===============
1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] www.analystsreview.com.
5. For any urgent concerns or inquiries, please contact us at compliance [at] www.analystsreview.com.
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] www.analystsreview.com for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts Review
